Which I'm not so keen on. I get that buying QIP (or any other firm) entrenches IPH as a dominant player in the market and adds revenue blah blah but the roll up strategy has had its hiccups for us and I feel like it might be time to take a breather, consolidate the existing business and particularly growth of the Asian firms. Is this really the right time for more debt/scrip?
Otherwise happy that IPH appears to have put H1 concerns to rest. SP has nearly completely recovered.
Ann: Sale of Filing Analytics and Citation Eagle products, page-11
Add IPH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
-0.060(1.17%) |
Mkt cap ! $1.578B | |||
| Open | High | Low | Value | Volume |
| $5.17 | $5.19 | $5.08 | $2.281M | 446.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 19240 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.10 | 2799 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IPH (ASX) Chart |
